-

Dr. Vince Clinical Research Now Green Certified

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research, a full-service Phase I-II contract research organization (CRO), announced its world-class clinical pharmacology unit, which opened in September, was awarded two Green Globes certifications.

Considering healthcare is responsible for nearly 5% of greenhouse emissions and air pollutants worldwide, Dr. Vince Clinical Research prioritized investing in long-term sustainability practices during the design and construction phase of the custom-built, green-inspired facility. As part of a comprehensive Green Globes certification process, everything from initial planning to HVAC optimization was executed in collaboration with Green Building Initiative (GBI) and Bell/Knott & Associates. Each area of the facility contains a host of intentionally designed integrations and technologies — considering environmental impacts — to achieve a more sustainable future for the clinical research industry.

“People commonly associate green building with energy efficiency, but sustainability involves much more,” said Green Globes Assessor David Johnson. “In addition to energy-efficient building systems, the facility achieved significant accomplishments in water conservation, renewable energy, resource conservation as well as indoor air quality. It was rewarding to work as a team to achieve their sustainability goals.”

A more sustainable space is a significant milestone for any organization, but it hasn’t become commonplace for all, especially for sites conducting clinical research.

“Dr. Vince Clinical Research strives to be a market leader in the clinical research industry by setting new standards,” said CEO and Medical Director Brad Vince, D.O. “We are proud of our well-designed space and inspired strategies to help reduce climate impact and contribute toward a greener future, and we hope to inspire other CROs to pursue environmentally sustainable practices as well.”

About Dr. Vince Clinical Research

Dr. Vince Clinical Research (DVCR) is a world-class full-service CRO (Contract Research Organization) with a custom-built, green-designed headquarters and research complex encompassing three buildings in Overland Park, KS. DVCR’s complex includes a 90-bed clinical pharmacology unit featuring a combination of luxurious and private research suites and a GMP compliant pharmacy with positive and negative pressure compounding rooms. DVCR specializes in conducting clinical trials for both healthy normal volunteers and patient populations in a wide variety of early phase trials. By leveraging both technology and one of the country’s most experienced leadership teams, DVCR provides Smarter, Faster Data to their biopharmaceutical clients.

Contacts

Zach Bader
Vice President, Business Development
(913) 333-3000
info@drvince.com

Dr. Vince Clinical Research


Release Summary
Dr. Vince Clinical Research announced its world-class clinical pharmacology unit was awarded two Green Globes certifications.
Release Versions

Contacts

Zach Bader
Vice President, Business Development
(913) 333-3000
info@drvince.com

Social Media Profiles
More News From Dr. Vince Clinical Research

Dr. Vince Clinical Research Appoints World-Renowned Drug Developer, Clinical Pharmacologist and Neuroscientist Dr. Sheldon Preskorn as Senior VP of Neuroscience

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research (DVCR) today announced the appointment of Sheldon Preskorn, M.D., as its Senior Vice President of Neuroscience....

Dr. Vince Clinical Research Announces First Dosing in a Phase II Study in Patients With Depression

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research announced the first dosing in a Phase II multicenter trial of SPN-820 in adults with major depressive disorder (MDD)....

Dr. Vince Clinical Research Launches New Solution for Organ Impairment Studies

OVERLAND PARK, Kan.--(BUSINESS WIRE)--Dr. Vince Clinical Research (DVCR) announced a new solution that will challenge the current landscape for managing organ impairment studies....
Back to Newsroom